Aetna, Guardian Ousted From Neurontin Off-Label MDL

Law360, New York (January 11, 2010, 2:50 PM EST) -- A federal judge has tossed Aetna Inc. and Guardian Life Insurance Co.'s claims against Pfizer Inc. and Warner-Lambert Co. in the multidistrict litigation alleging that Pfizer and Warner-Lambert engaged in a fraudulent, anti-competitive scheme to market their anti-epilepsy drug Neurontin for off-label conditions.

Judge Patti B. Saris of the U.S. District Court for the District of Massachusetts on Friday granted Pfizer and Warner-Lambert's motion for summary judgment as to Guardian and Aetna's claims of fraud, racketeering and unfair competition, but allowed Kaiser Foundation Health Plan Inc....
To view the full article, register now.